Skip to content

    Tatva Chintan

    TATVA
    Chemicals·24 Jul 2025
    Management Summary

    Tatva Chintan reported a strong Q1 FY26, with operating revenue growing 11% YoY to INR1,169 million and EBITDA surging 37% YoY to INR173 million, driven by improved business sentiment and margin expansion. Key segments like SDA and PASC showed robust growth and new product commercialization, while Electrolyte Salts and Semiconductors made significant developmental strides. Despite challenges from geopolitical uncertainties and value erosion in SDA pricing, the company maintains a positive outlook for coming quarters, supported by R&D focus and strategic investments.

    Highlights

    8
    • Operating revenue of INR1,169 million, up 11% year-on-year and 8% quarter-on-quarter.

    • EBITDA came in at INR173 million, reflecting a 37% year-on-year rise and a 94% growth as compared to previous quarter.

    • EBITDA margin increased by 287 bps year-on-year basis to 14.8%.

    • PAT grew to INR66 million from INR52 million in Q1 FY25, with PAT margins at 5.7% vs 4.9%.

    • Structure Directing Agents (SDA) segment showed a 14% QoQ and 13% YoY growth, with strong demand visibility and Euro 7 norm tailwinds.

    • Pharma & Agro Intermediates and Specialty Chemicals (PASC) revenue grew 32% QoQ and 11% YoY, with new agro intermediates entering commercialization in Q3 FY26.

    • Electrolyte Salts saw a 32% QoQ revenue rise and secured a first small-scale commercial order for extended validations in the energy storage market.

    • Semiconductors segment achieved successful pilot scale sample supply, generating strong industry interest.

    Concerns

    5
    • Phase Transfer Catalyst (PTC) revenue declined 17% on a quarterly basis.

    • Electrolyte Salts revenue dipped 12% year-on-year.

    • Global geopolitical landscape remains fragile, and uncertainties persist regarding U.S. reciprocal tariffs.

    • SDA pricing continues to be at non-viable levels due to cheap raw materials, leading to value erosion.

    • CFO, Mr. Ashok Bothra, is relocating and leaving the company.

    What Changed2

    vs Q3 FY26

    Guidance items11 → 13 (+2)Risks discussed4 → 5 (+1)

    Key financials

    Single quarter

    08 metrics
    1. 01Operating Revenue1,169 Mn+11%YoY
    2. 02EBITDA173 Mn+37%YoY
    3. 03EBITDA Margin14.8%+23.7%YoY
    4. 04PAT66 Mn+26.9%YoY
    5. 05PAT Margin5.7%+16.3%YoY

    Segment breakdown

    • Phase Transfer Catalyst323 Mn27.8%
    • Electrolyte Salts12 Mn1.0%
    • Pharma & Agro Intermediates and Specialty Chemicals432 Mn37.2%
    • Structure Directing Agents394 Mn33.9%
    Donut· Share of Revenue

    Capital allocation

    1
    high confidence
    CategoryHeadline
    Capex

    ₹110 crores

    Guidance & targets

    13
    CategoryTargetPriority
    Volume
    SDA Volume Growth
    40% to 70%
    High
    Profitability
    SDA Margin
    as good as our SDA segment
    Medium
    Profitability
    Electrolyte Salts Margin
    as good as our SDA segment
    Medium
    Revenue
    Electrolyte Salts Peak Revenue (existing facility)
    INR100 crores
    Medium
    Revenue
    Electrolyte Salts Contribution to Top Line
    roughly about 10%
    Medium
    Revenue
    Electrolyte Salts Revenue
    INR15 crores to INR20 crores
    Medium
    Revenue
    FY26 Revenue Growth
    upward of 25%
    High
    Revenue
    FY27 Revenue Growth
    20% to 25%
    Medium
    Margin
    FY26 Margin
    20%
    High
    Margin
    FY27 Margin
    20% level
    Medium
    Commercialization
    Semiconductor Commercialization
    slow commercialization to begin in 2027, full-scale by 2029
    High
    Commercialization
    Agro Intermediates Commercialization
    start producing from August, beginning supplies from November
    High
    Commercialization
    Pharma Intermediates Commercialization
    August or September of 2026
    High

    SDA Volume & Revenue Growth

    Next quarter (Q2 FY26)
    Current14% QoQ, 13% YoY growth in Q1 FY26
    TargetContinued growth towards 40-70% volume increase, with stronger demand in Q2/Q3

    Why it matters

    SDA is a key segment, and its recovery and growth are crucial for overall performance and margin expansion.

    We see stronger demand coming in Q2 and Q3. That is the visibility which we already have.

    How to verify

    key_financials.segment_breakdown[name='Structure Directing Agents'].metrics[label='Revenue']

    Risks & concerns

    5
    RiskSeverity

    Global geopolitical landscape and U.S. reciprocal tariffs

    The global geopolitical landscape remains fragile and uncertainties persist pertaining to U.S. reciprocal tariffs, requiring caution.Management acknowledged

    medium

    SDA value erosion due to cheap raw materials

    SDA prices remain at non-viable levels due to cheap raw materials, impacting value, though volumes are expected to grow.Management acknowledged

    medium

    Teething issues in PASC production volumes

    Initial production issues are being resolved to move towards smooth production cycles for PASC products.Management acknowledged

    low

    Long commercialization timeline for semiconductor products

    Semiconductor products require years of development, scale-ups, and validations, with full commercialization not expected until 2029.Management acknowledged

    medium

    CFO transition

    Mr. Ashok Bothra, CFO, is relocating and pursuing another opportunity, leading to a change in financial leadership.Management acknowledged

    medium

    Q&A highlights

    8

    “So, the price of our SDA still continues to remain at the same level. In terms of demand, still the Chinese demand is nearly negligible, whereas the U.S. and the Europe demands have actually picked up.”

    Clarifies the current state of SDA pricing and demand by geography, indicating a shift away from China dependence.

    asked by Sudarshan Padmanabhan

    2 min read6 chapters

    Detailed Narrative

    01

    Q1 FY26 Financial Performance Overview

    Tatva Chintan reported a robust Q1 FY26, with operating revenue reaching INR1,169 million, an 11% increase year-on-year and 8% quarter-on-quarter. EBITDA surged to INR173 million, marking a 37% YoY and 94% QoQ rise, leading to a significant EBITDA margin expansion of 287 bps YoY to 14.8%. Net profit stood at INR66 million, up from INR52 million in Q1 FY25, with PAT margins at 5.7%. Exports contributed 71% of the revenue, totaling INR830 million.

    02

    Segmental Performance and Outlook

    The Structure Directing Agents (SDA) segment recorded INR394 million in revenue, growing 14% QoQ and 13% YoY, with management expecting continued growth driven by Euro 7 norms and strong demand visibility. The Pharma & Agro Intermediates and Specialty Chemicals (PASC) segment delivered INR432 million in revenue, up 32% QoQ and 11% YoY, with new agro intermediates entering commercialization in Q3 FY26. Phase Transfer Catalyst (PTC) revenue was INR323 million, declining 17% QoQ but growing 9% YoY, while Electrolyte Salts, at INR12 million, rose 32% QoQ but dipped 12% YoY, with commercial orders for extended validations secured.

    03

    Strategic Focus on R&D and Innovation

    The company emphasized its core focus on strengthening R&D capabilities, viewing scientific innovation as the most sustainable path to value creation. This approach has led to interesting developmental opportunities and recognition from customers. The semiconductor segment, a result of years of dedicated R&D, successfully supplied pilot scale samples meeting customer requirements, with further repeat pilot runs requested to demonstrate consistency, aiming for slow commercialization from 2027 to 2029.

    04

    Capex and R&D Investments

    Tatva Chintan has a capex plan of INR110 crores for the current financial year (FY26), primarily for a new block to accommodate missing parts for agro intermediates. The R&D expenditure, excluding capex, is estimated to be between INR4-5 crores, representing 1% to 1.5% of revenue, reflecting a long-term investment in product development, particularly in niche areas like semiconductors and electrolytes.

    05

    Market Dynamics and Challenges

    Management acknowledged the fragile global geopolitical landscape and uncertainties regarding U.S. reciprocal tariffs, remaining cautious about potential abrupt changes. While China demand for SDA remains negligible, the company anticipates a rebound in diesel engine demand in China. The SDA segment continues to face value erosion due to cheap raw materials, keeping prices at non-viable levels, though volumes are expected to grow.

    06

    Management Transition

    The company announced that its CFO, Mr. Ashok Bothra, has decided to relocate and pursue another opportunity. Management expressed gratitude for his contributions and wished him well, indicating a transition in the financial leadership.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.